Reevaluation of the two-component hypothesis for turning behaviour by manipulating activities in the striatum and the nucleus accumbens of intact rats.
The role of dopamine D1 and D2 receptor stimulation in the production of turning behaviour in rats was studied. In rats pretreated with unilateral injections of the non-selective dopamine D1/D2 receptor antagonist, cis(Z)-flupentixol (10 micrograms/0.5 microliter), into the ventral striatum, quinpirole (1, 3, 5, 10 mg/kg i.p.), a selective dopamine D2 receptor agonist, induced dose-dependent turning behaviour, while SKF 38393 (1, 3, 5, 10 mg/kg i.p.), a selective dopamine D1 receptor agonist, did not. The effect of the two drugs together was much greater than the effect of quinpirole alone and was reduced by additional blockade of dopamine D1/D2 receptors in either the ipsilateral or contralateral nucleus accumbens. The role of the nucleus accumbens in turning behaviour was determined from the effects of unilateral injections of SKF 38393 and quinpirole into the nucleus accumbens. The results show that unilateral injections of a mixture of the two drugs (SKF 38393 5 micrograms + quinpirole 10 micrograms/0.5 microliter) into the nucleus accumbens produced turning while injections of single drugs did not. Turning was abolished by the blockade of dopamine D1/D2 receptors in the ipsilateral but not contralateral ventral striatum. Turning was also reduced by the blockade of the contralateral nucleus accumbens. Moreover, turning was not produced by injections of the drug mixture into the dorsal or ventral striatum.
Saigusa
T
T
Department of Pharmacology, Nihon University School of Dentistry, Tokyo, Japan.
Koshikawa
N
N
Kitamura
M
M
Kobayashi
M
M
D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine / Q000008:administration & dosage / Q000494:pharmacology; D000818:Animals; D003342:Corpus Striatum / Q000187:drug effects / Q000473:pathology / Q000502:physiology*; D015259:Dopamine Agents / Q000494:pharmacology*; D004357:Drug Synergism; D004873:Ergolines / Q000008:administration & dosage / Q000494:pharmacology; D005475:Flupenthixol / Q000008:administration & dosage / Q000494:pharmacology; D007274:Injections, Intraperitoneal; D008297:Male; D009043:Motor Activity / Q000187:drug effects / Q000502:physiology*; D009714:Nucleus Accumbens / Q000187:drug effects / Q000473:pathology / Q000502:physiology*; D019257:Quinpirole; D051381:Rats; D017208:Rats, Wistar; D017447:Receptors, Dopamine D1 / Q000187:drug effects / Q000502:physiology*; D017448:Receptors, Dopamine D2 / Q000187:drug effects / Q000502:physiology*
D015259:Dopamine Agents; D004873:Ergolines; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D019257:Quinpirole; D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; D005475:Flupenthixol